BioCentriq expands executive leadership; appoints Jennifer Manning as COO 

Newark-based BioCentriq on Wednesday said it appointed Jennifer Manning as chief commercial officer, effective immediately.

“We are thrilled to welcome Jennifer to the BioCentriq leadership team,” BioCentriq founder and CEO Haro Hartounian said. “Jennifer is a driven and energetic leader with a track record of building high-performing business development teams. She brings a wealth of expertise that will be instrumental in driving BioCentriq’s growth and success. Jennifer’s leadership, long-term vision and dedication to fostering strategic partnerships align perfectly with our mission to accelerate the development and manufacture of life-changing immunotherapies.”

Manning’s 25 years of life sciences experience spans biotech and contract development and manufacturing organizations. Most recently, she served as the senior vice president of global strategic partnerships at the Center for Breakthrough Medicines. Before joining CBM, she held the position of executive director, commercial development, at Fujifilm Diosynth Biotechnologies, where she was responsible for building and leading the North American Advanced Therapies commercial development team.

Earlier in her career, Manning held commercial roles of increasing responsibility at Lonza, Alcami Corp., Patheon and DSM Biologics. She played a pivotal role during the commercial launch of Human Genome Science’s BENLYSTA and spent 14 years at Abbott Laboratories (now AbbVie), where she was heavily involved in the successful launch and commercialization of HUMIRA.

“I am honored and excited to join the BioCentriq leadership team. This opportunity complements my passion for innovation and my deep personal commitment to providing groundbreaking treatments to patients,” Manning said. “With proven expertise in allogeneic and autologous process development and a demonstrated track record of successfully manufacturing and releasing clinical drug product, the BioCentriq team and its partners are well positioned to shape the future of cell therapy and make a significant, and lasting impact on health care and patients’ lives.”